Cadence Pharma raises $71.3M in offering, to support Ofirmev launch
This article was originally published in Scrip
Executive Summary
Cadence Pharmaceuticals, which in-licenses hospital products and continues with a US rollout of its Ofirmev IV acetaminophen, said it expects proceeds of about $67.4 million, after expenses, in an underwritten public offering that raised $71.3 million.